G D Demetri
Affiliation: Harvard University
- Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study GroupG D Demetri
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 16:3412-25. 1998..To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate these changes with antitumor response...
- Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapyG D Demetri
Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Br J Cancer 84:31-7. 2001..With this new option for therapy, further avenues of investigation should lead to renewed interest in the clinical benefits of optimal haemoglobin levels for patients with cancer...
- Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinibS George
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Ann Oncol 23:3180-7. 2012..Hypertension (HTN), an on-target class effect of vascular endothelial growth factor signaling-pathway inhibitors, has been shown to correlate with clinical outcome in advanced renal cell carcinoma treated with sunitinib...
- Targeted approaches for the treatment of thrombocytopeniaG D Demetri
Dana Farber Cancer Institute, Boston, Massachusetts 02115 6084, USA
Oncologist 6:15-23. 2001..As a potent stimulator of platelet production, rHuTPO has the potential to reduce the need for platelet transfusions and their attendant complications...